US · Healthcare · Biotechnology
EPS came in at -0.93 against a street estimate of -1.11 — a beat of 16.2%.
Analysts rate Arrowhead Pharmaceuticals Inc a buy (11 buy, 2 hold, 0 sell out of 13) with an average price target of $108.09.
| Fund | Stake |
|---|---|
| BlackRock Inc | 12.89% |
| venBio Select Advisor LLC | 7.60% |
| FMR Inc | 5.16% |
| Vanguard Portfolio Management, LLC | 5.07% |
| State Street Corp | 4.61% |
| Vanguard Capital Management, LLC | 4.28% |
| Geode Capital Management, LLC | 3.04% |
| Fred Alger Management, LLC | 2.37% |
| Document | Date |
|---|---|
| Board / officer change · Q2 2026 | 2026-06-16 |
| Quarterly report · Q1 2026 | 2026-05-07 |
| Results announced · Q2 2026 | 2026-05-07 |
| Shareholder vote results · Q1 2026 | 2026-03-20 |
| Quarterly report · Q4 2025 | 2026-02-05 |
| Results announced · Q1 2026 | 2026-02-05 |
| Proxy statement · Q1 2026 | 2026-01-27 |
| Annual report FY2025 | 2025-11-25 |
Readable in the app.
| Announcement | Date |
|---|---|
| FDA approves REDEMPLO for familial chylomicronemia syndrome treatment Arrowhead Pharmaceuticals announced FDA approval of REDEMPLO® (plozasiran) on November 18, 2025. REDEMPLO is a new drug designed to reduce triglycerides in adults with familial chylomicronem | 2025-11-18 |
| Exclusive licensing and collaboration agreement with Novartis for ARO-SNCA Arrowhead Pharmaceuticals signed an exclusive licensing and collaboration agreement with Swiss pharmaceutical giant Novartis on September 2, 2025. Under this deal, Novartis receives exclusiv | 2025-09-02 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Arrowhead Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.